Kishina et al. 9 reported that aliskiren reduced hepatic steatosis in Shionogi-ob/ob mice, however they only measured the hepatic mRNA expressions of SREBP1c, MTP and PPAR-α, and no differences were found between the aliskiren and control groups. This evidence concerns the gene SREBF1 and fatty liver disease.